The unique mechanism of HIF-PH inhibitors, which increases endogenous erythropoietin and addresses iron utilization dysfunction, may offer particular benefits for this population, given that these factors are primary contributors to anemia in heart failure [19]. The gene discussed is EPO; the disease is anemia.